Multidisciplinary patient-centered networks offer access to difficult-to-get samples and initiate projects from human material. Improving such networks to include 'living' samples could be transformative, not only for research but for clinical trial design, especially when focused on unmet clinical needs, such as brain metastasis.
Keywords: biobank; drug-screening; network; omics; patient-derived organotypic culture (PDOC); personalized medicine.
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.